The World Health Organization (WHO) has warned that levels of measles vaccination are not high enough to prevent fatal outbreaks from occurring.
Thirty-five people died in Europe last year as a result of the disease, which is characterized by a cough, sore throat and skin rash and a high fever that can be life-threatening to young children.
Globally, death rates have declined as more people receive the measles vaccine, but it is still responsible for over 100,000 fatalities per year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze